Congenital Syphilis Elimination Cost-Effectiveness Analysis
Location(s): Burundi; Comoros; Djibouti; Madagascar; Malawi; Mauritius; Mozambique; Rwanda; Tanzania; Zambia; Zimbabwe; Cameroon; Central African Republic; Chad; Congo (Brazzaville); Gabon; Sao Tome and Principe; Sudan; Tunisia; Botswana; Namibia; South Africa; Swaziland; Benin; Burkina Faso; Ivory Coast; Ghana; Guinea; Mali; Nigeria; Sierra Leone; Togo; Kazakhstan; Kyrgyzstan; Uzbekistan; China; Mongolia; Afghanistan; Bangladesh; India; Maldives; Nepal; Sri Lanka; Cambodia; Indonesia; Viet Nam; Laos; Malaysia; Myanmar; Thailand; Philippines; Jordan; Oman; Saudi Arabia; Belarus; Czech Republic; Estonia; Germany; Hungary; Lithuania; Macedonia; Moldova; Romania; United Kingdom; Costa Rica; El Salvador; Guatemala; Honduras; Mexico; Panama; Argentina; Bolivia; Brazil; Chile; Colombia; Ecuador; Guyana; Paraguay; Peru; Uruguay; Antigua and Barbuda; Cuba; Dominica; Dominican Republic; Grenada; Trinidad and Tobago; Fiji; Kiribati; Papua New Guinea